Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep
Mrinalini Dey DrMiniDey
4 years ago
Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21
⏰19:00 ET
⏰Midnight GMT- I promise to be well-caffeinated to present my many highlights from today! 😄
📺Register via the Zoom link below or watch on Youtube https://t.co/6HIQGR5T8z
David Liew drdavidliew
4 years ago
beautifully chaired by @cappelliMD
also elegant talk on 'M-triad' by the always articulate @lovetolearn27, made me think about my pt on the ward right now!
#ACR21 @RheumNow @CCalabreseDO @LCalabreseDO @got_rheum @MarieKostine @lexmeara @ReidMDMPH @NilashaGhosh @RheumDr_Nina https://t.co/2iu6zWp8Ge
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
*️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX)
⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA)
→2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P
*️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched
Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS
David Liew drdavidliew
4 years ago
Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs:
similar:
- importance of confirming dx well
- cautious adoption steroid-sparing Rx
different:
- clear benefit hard/early Rx
- dx metrics aided by tech
#ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #COVID19 vaccines in people with #lupus @RheumNow https://t.co/pru9dTH4z7
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts
➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated!
Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q
Akhil Sood MD AkhilSoodMD
4 years ago
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients
Rubbert-Roth and colleagues found:
- RA patients developed anti-S1 antibodies slower and lower compared to controls
- Reduced titers among Abatacept & JAKi users
#ACR21 @RheumNow https://t.co/sXW8d53O8m
Dr. John Cush RheumNow
4 years ago
Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below.
https://t.co/sxQuP28APX
Or visit our YouTube channel-RheumNow.
https://t.co/sohrPTB16S https://t.co/LXWaBFOdHO
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Post-Hoc of ASCORE trial:
➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz
➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below!
Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW
Bella Mehta bella_mehta
4 years ago
Cathepsin K - has some promise in Knee OA - now going to Phase 3
@RheumNow https://t.co/exUFqcCJy1


Poster Hall